Recent AIM News
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 11/08/2024 10:27:06 PM
- Form DEFC14A - Definitive proxy statement, contested solicitations • Edgar (US Regulatory) • 11/06/2024 02:02:05 PM
- AIM ImmunoTech to Discuss Third Quarter 2024 Financial Results on November 15, 2024 and Host Conference Call and Webcast • GlobeNewswire Inc. • 11/06/2024 02:00:00 PM
- AIM ImmunoTech Files Definitive Proxy Statement and Sends Letter to Shareholders • Business Wire • 11/04/2024 01:00:00 PM
- Form DEFC14A - Definitive proxy statement, contested solicitations • Edgar (US Regulatory) • 11/04/2024 12:00:16 PM
- Form PRER14A - Preliminary Proxy Soliciting materials • Edgar (US Regulatory) • 10/30/2024 08:50:29 PM
- Form PRRN14A - Non-management revised preliminary proxy soliciting materials, contested and otherwise • Edgar (US Regulatory) • 10/30/2024 04:53:26 PM
- Form PREC14A - Preliminary proxy statements, contested solicitations • Edgar (US Regulatory) • 10/18/2024 08:34:17 PM
- Form PREC14A - Preliminary proxy statements, contested solicitations • Edgar (US Regulatory) • 10/15/2024 08:33:31 PM
- AIM ImmunoTech to Participate in the 2024 Healthcare Virtual Summit, Presented by Maxim Group LLC • GlobeNewswire Inc. • 10/09/2024 01:00:00 PM
- AIM ImmunoTech Granted U.S. Patent for Ampligen® for the Treatment of Endometriosis • GlobeNewswire Inc. • 10/03/2024 12:45:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/01/2024 07:55:19 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 10/01/2024 05:12:28 PM
- AIM ImmunoTech Announces Pricing of $1.26 Million Registered Direct Offering • GlobeNewswire Inc. • 09/30/2024 01:00:00 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 09/30/2024 12:22:43 PM
- AIM ImmunoTech to Participate in Virtual Investor CEO Connect Segment • GlobeNewswire Inc. • 09/27/2024 12:00:00 PM
- AIM ImmunoTech Reports Positive Preliminary Data in Phase 1b/2 Study of Ampligen and Imfinzi as a Combination Therapy for Late-Stage Pancreatic Cancer • GlobeNewswire Inc. • 09/19/2024 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/17/2024 04:05:17 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/16/2024 07:45:11 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/12/2024 09:15:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/12/2024 08:45:37 PM
- Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend] • Edgar (US Regulatory) • 09/11/2024 09:40:58 PM
- AIM ImmunoTech Announces that Analysis of AMP-518 Complete Clinical Patient Data Underscores Ampligen’s Potential to Improve the Post-COVID Condition of Fatigue • GlobeNewswire Inc. • 09/11/2024 01:00:00 PM
- Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend] • Edgar (US Regulatory) • 09/04/2024 01:43:58 AM
- AIM ImmunoTech Announces Print Publication and Further Positive Findings from a Study Evaluating Ampligen® in the Treatment of Pancreatic Cancer in the Journal Clinical Cancer Research • GlobeNewswire Inc. • 08/20/2024 12:30:00 PM
SANUWAVE Announces Record Quarterly Revenues: Q3 FY2024 Financial Results • SNWV • Nov 8, 2024 7:07 AM
DBG Pays Off $1.3 Million in Convertible Notes, which Retires All of the Company's Convertible Notes • DBGI • Nov 7, 2024 2:16 PM
SMX and FinGo Enter Into Collaboration Mandate to Develop a Joint 'Physical to Digital' Platform Service • SMX • Nov 7, 2024 8:48 AM
Rainmaker Worldwide Inc. (OTC: RAKR) Announces Successful Implementation of 1.6 Million Liter Per Day Wastewater Treatment Project in Iraq • RAKR • Nov 7, 2024 8:30 AM
SBC Medical Group Holdings and MEDIROM Healthcare Technologies Announce Business Alliance • SBC • Nov 7, 2024 7:00 AM
VAYK Confirms Insider Buying at Open Market • VAYK • Nov 5, 2024 10:40 AM